Cargando…

Solid-State NMR Structure of a Pathogenic Fibril of Full-Length Human α-Synuclein

Misfolded α-synuclein amyloid fibrils are the principal components of Lewy bodies and neurites, hallmarks of Parkinson’s disease (PD). Here we present a high-resolution structure of an α-synuclein fibril, in a form that induces robust pathology in primary neuronal culture, determined by solid-state...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuttle, Marcus D., Comellas, Gemma, Nieuwkoop, Andrew J., Covell, Dustin J., Berthold, Deborah A., Kloepper, Kathryn D., Courtney, Joseph M., Kim, Jae K., Barclay, Alexander M., Kendall, Amy, Wan, William, Stubbs, Gerald, Schwieters, Charles D., Lee, Virginia M. Y., George, Julia M., Rienstra, Chad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034296/
https://www.ncbi.nlm.nih.gov/pubmed/27018801
http://dx.doi.org/10.1038/nsmb.3194
Descripción
Sumario:Misfolded α-synuclein amyloid fibrils are the principal components of Lewy bodies and neurites, hallmarks of Parkinson’s disease (PD). Here we present a high-resolution structure of an α-synuclein fibril, in a form that induces robust pathology in primary neuronal culture, determined by solid-state NMR spectroscopy and validated by electron microscopy and X-ray fiber diffraction. Over 200 unique long-range distance restraints define a consensus structure with common amyloid features including parallel in-register β-sheets and hydrophobic core residues, but also substantial complexity, arising from diverse structural features: an intermolecular salt bridge, a glutamine ladder, close backbone interactions involving small residues, and several steric zippers stabilizing a novel, orthogonal Greek-key topology. These characteristics contribute to the robust propagation of this fibril form, as evidenced by structural similarity of early-onset PD mutants. The structure provides a framework for understanding the interactions of α-synuclein with other proteins and small molecules to diagnose and treat PD.